Immune Pharmaceuticals raises $11.7m on Nasdaq
Filing for patents in Switzerland could save Teva billions of shekels in tax.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) is stopping filing for patents in Israel for products developed in the country and will file for them in Switzerland instead. The step will enable the pharmaceutical giant to benefit from tax exemptions and incentives that are granted in Switzerland but are not available in Israel for development, manufacturing and registering patents, sources inform "Globes."
As "Globes" revealed earlier this year, Teva has paid virtually zero tax in Israel due to the Law for the Encouragement of Capital Investment which benefits companies manufacturing in Israel. However, for registering patents without subsequent manufacturing, Israel offers no tax benefits. Furthermore, production activities that are not completely undertaken in Israel and are part of the chain that include activities by companies abroad, are also not eligible for tax breaks.
In contrast Switzerland grants tax breaks for companies that are only filing for patents and not manufacturing in the country and conducts a tax breaks regime whereby products only partly manufactured in the country enjoy far reaching tax incentives if certain conditions are met.
"Globes" has also been informed that top executives at Teva contacted senior government officials to investigate the possibility of establishing a similar tax break mechanism in Israel for solely registering patents as exists in Switzerland. The possibility is being examined but it is thought unlikely that the tax incentive will be granted.
The main reason for reluctance to introduce such a tax break is that to create a benefit for solely registering patents without the need for manufacturing could result in factories being transferred out of Israel. Finance Ministry sources also explain that it is unacceptable to create tax policies based on the needs of a single company. Teva, as reported, plans taking advantage of the Swiss tax regime for registering patents and its company's activities abroad, and consequently Israel will lose revenue from patent registration. Huge profits
Luzzatto & Luzzatto Patent Attorneys managing partner Dr. Esther Luzzatto said, "Developing a drug costs on average close to a billion dollars. But the profits are also huge. We're talking about big money. Every successful drug rakes in billions of dollars a year while the patent is still valid."
Teva has a number of patents including that of its flagship drug Copaxone for treating multiple sclerosis. Teva is also very active in the generics sector developing treatments based on drugs where the patent has expired. Here too in developing generic drugs Teva has registered its own patents on the things it developed itself from the patent taken from another company.
Luzzatto said, "In this way Teva obtains an advantage for its treatments over others in the market. Every advantage gained by a product is significant and rakes in big money for the drug. This is a war over a lot of money."
And all these billions of dollars are subject to tax. A saving of several percentage points can bring hundreds of millions of dollars into a company's coffers. Teva's "departure" from Israel is affected by the volume of tax breaks that the company receives under the Law for the Encouragement of Capital Investment as a "preferred enterprise." The Israeli law competes with rival nations worldwide. Israel's tax levels are similar to other countries so that tax levels are about 6% in Switzerland, 10% in the UK, and 6% in Israel although the Economic Arrangements bill proposes hiking it to 10%.
Teva's problem is not the percentage of tax it pays but rather the company's ability to maximize the tax breaks it receives. A source that understands tax considerations said, "The problem is not where tax is higher but what is defined as revenue that enjoys tax breaks. The definition in Israel is very narrow. We are talking about a law regarding production in Israel based on industrial activities in the country. When we look at global companies like Teva with activities partly carried out in Israel but that buy raw ingredients abroad, and some of their activities are carried out by third parties, in such a situation the company does not enjoy tax breaks."
In other words according to the current interpretation by income tax, the question of what is production in Israel for Teva, which is a multinational with a chain of production encompassing countries overseas, means it won't enjoy tax benefits for patents and developments in this international chain.
In contrast Switzerland encourages companies to register their intellectual property and patents and manage their supply chain in Switzerland where production can be partly conducted. Tax break are offered providing management is carried out from Switzerland by at least 25 employees.
A well-known accountant told "Globes," "According to Switzerland's tax policies, the company will enjoy tax benefits on profits and this will attract all its profits to Switzerland where it will pay minimal tax of between 0% and 10%, usually 6%. This is very much suits global companies because they have companies and production personnel in many countries and they all provide production services to the same company so that managing the supply chain in Switzerland brings all profits to Switzerland and everybody gains. The Swiss gain a lot of jobs and tax revenue, and the companies can operate out of a main European country with very low tax rates."
Teva said in response, "We wish to emphasize that Teva's intellectual property registered or developed in Israel will remain here. Teva's IP, as gained from developments and acquisitions that were performed worldwide, is registered in different countries. This policy remains unchanged. Teva will be more than happy to transfer to Israel its IP assets developed and registered in other countries, should the Israeli tax regulations allow more competitive tax rates compared with other countries."
Published by Globes [online], Israel business news - www.globes-online.com - on June 18, 2013
© Copyright of Globes Publisher Itonut (1983) Ltd. 2013
You comment was recieved and soon will be published.
Load more comments
The money raised will fund a Phase II trial of ulcerative colitis drug bertilmumab.
XTL Biopharma files to raise $40m on Nasdaq
XTL plans to initiate a large Phase IIb clinical trial for the treatment of Lupus.
Teva launches generic cancer drug
Brand Xeloda, made by Genentech, had $754 million in US sales in 2013.
Yelin Lapidot takes stake in Brainsway
Brainsway raised NIS 41 million in the private placement.
Barclays upgrades Teva
Barclays raised its recommendation to "Overweight" and its target price to $65.
BiolineRX raises $24m in Nasdaq offering
Three months ago, the company announced promising preliminary clinical trial results.
Teva VP Ika Abravanel resigns
Abravanel's is the first senior departure from Teva since Erez Vigodman became CEO.
FDA approves Pluristem cell production facility
Pluristem's Haifa plant can produce 150,000 doses of PLX cells annually.
Desheh: Splitting Teva will not create value
Teva CFO Eyal Desheh says Teva's tight integration means that a split makes no sense.
InsuLine expanding in Europe
24Care will distribute the company's InsuPad product in the Netherlands and Belgium.
Teva launches generic breast cancer, osteoporosis drug
Teva has 180 days of marketing exclusivity for generic Evista, which had 2013 US sales of $824 million.
BiolineRX raising $21m in Nasdaq secondary offering
The company will use the proceeds to develop leukemia and celiac disease drugs.
MediWound sets terms for $92m Nasdaq IPO
The burns and wounds treatment developer's offering is at a value of $350-370 million.
Opko losses triple
CEO Phillip Frost: From an R&D perspective, all our programs are progressing.
D-Pharm doubles on good interim stroke study results
The Phase IIa trial interim results found the company's drug was safe for cerebral strokes.
Perrigo selling OTC drugs through Amazon
Perrigo: It is also a platform for obtaining good information about consumer behavior.
Teva launches bipolar, schizophrenia treatment
Adasuve is the first orally inhaled medicine for the acute treatment of agitation in schizophrenia and bipolar I disorder.
Perrigo acquires Aspen Global products for $51m
Perrigo bought value-brand OTC products sold in Australia and New Zealand.
Galmed updates $30m Nasdaq IPO prospectus
The liver disease drug developer will issue shares at a company value of $132 million.
Enzymotec shareholders raise $131m in offer to sell
Kibbutz Ma'anit's Galam reportedly sold shares for $46 million.
Compugen raises $63m, Magic $51m
The two companies held secondary offerings on Nasdaq on the basis of shelf prospectuses.
If Rose Fostanes played basketball
Reforms in regulations for foreign caregivers are welcome, but don't go far enough.
Private treatment kills public healthcare
If the German Committee validates private healthcare, it will be the last nail in public healthcare's coffin, argues Prof Dani Filc.
Reducing the number of polyps that colonoscopies miss
EndoChoice's Israel development center has devised an endoscope with a 330-degree arc.
Neopharm moves into orphan drugs
The company, better known for marketing others' products, has been quietly building up its innovative capacity, as VP Tal Fuhrer relates..
Merck Serono Israel incubator nurtures early stage projects
Merck Germany head of pharmaceuticals Dr. Stefan Oschmann says R&D is enjoying a renaissance at big pharma companies.
Israeli biomed cos bring in US CEOs
"Globes" speaks to 3 US CEOs appointed to boost marketing at TASE traded medical device companies.
Alcobra has had two successful Nasdaq offerings this year as it develops an ADHD treatment with fewer side effects.
Restructuring can help Teva's Copaxone woes
Avishai Ovadia argues that Teva can offset falling Copaxone sales by reducing overall company costs.
Enabling diabetes patients to sleep soundly
Excess insulin levels can be fatal when they occur at night. NightSense aims to remove the fear.